rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Hyperfine, Inc.

HYPR · Nasdaq

Health CareMedical DevicesNot moving yet

HYPR stood above a rising 150-day average in 15 of the last 52 weekly readings, and has been out of that trend for the last 15 weeks. It is 32.4% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 15
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$185K
Officials’ trades on record
0
Institutions holding
80 (+32)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 15 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$113K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months8
Buyers · sellers0 · 2
WhoDidSharesTraded
Brett HaleCFO and CAOsold7,345at $0.85424 Aug 2026filed 25 Aug 2026
Thomas TeisseyreChief Operating Officersold7,345at $0.85424 Aug 2026filed 25 Aug 2026
Thomas TeisseyreChief Operating Officersold6,047at $1.6526 May 2026filed 27 May 2026
Brett HaleCFO and CAOsold6,047at $1.6526 May 2026filed 27 May 2026
Brett HaleCFO and CAOsold24,188at $1.2123 Mar 2026filed 25 Mar 2026
Thomas TeisseyreChief Operating Officersold24,188at $1.2123 Mar 2026filed 25 Mar 2026
Thomas TeisseyreChief Operating Officersold821at $1.1113 Feb 2026filed 17 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders80+32 on the quarter
New · exited39 · 7
Reported value$29.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20264,673,087$6.3M+4,098,184+712.8%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20263,380,087$4.6M-73,076−2.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,960,811$2.6M+1,005,551+105.3%
Fosun International Ltdunchanged · filed 12 Aug 20261,742,020$2.4M00.0%
Catalio Capital Management, LPunchanged · filed 14 Aug 20261,320,041$1.8M00.0%
STATE STREET CORPadded · filed 7 Aug 20261,016,970$1.4M+692,900+213.8%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026945,836$1.3M+215,603+29.5%
Alphabet Inc.unchanged · filed 7 Aug 2026898,720$1.2M00.0%
NORTHERN TRUST CORPadded · filed 13 Aug 2026633,054$855K+455,686+256.9%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026567,109$766K+40,403+7.7%
31 Mar 2023 – 30 Jun 2026
325578Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Brett Hale Company insiderCFO and CAO · last 24 Aug 20260 · 3
Thomas Teisseyre Company insiderChief Operating Officer · last 24 Aug 20260 · 15
Dan Wolterman Company insiderDirector · last 3 Jun 20260 · 0
John T. Dahldorf Company insiderDirector · last 22 May 20260 · 0
Jonathan M. Rothberg Company insiderDirector, 10% owner · last 22 May 20267 · 0
Ruth A. Fattori Company insiderDirector · last 22 May 20260 · 0
Maria Sainz Company insiderPresident and CEO · last 31 Mar 20263 · 0
R. Scott Huennekens Company insiderDirector · last 12 Jun 20240 · 0
Khan Siddiqui Company insiderCMO and Chief Strategy Officer · last 16 Aug 20230 · 6
Alok Gupta Company insiderChief Financial Officer · last 16 Feb 20230 · 3
Joseph Patrick Healey Company insider10% owner · last 16 Dec 20227 · 0
Neela Paykel Company insiderGen Counsel & Corp Secretary · last 16 Nov 20220 · 3

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202549.8%
Operating profit marginFY 2025 · to 31 Dec 2025-273%
Free cash flow marginFY 2025 · to 31 Dec 2025-215%
Return on capital employedFY 2025 · to 31 Dec 2025-85.2%
Research spendFY 2025 · to 31 Dec 2025129%
Cash and equivalentsFY 2025 · to 31 Dec 2025$35.1M
Free cash flowFY 2025 · to 31 Dec 2025−$29.1M

Analyst forecasts

No analyst forecasts yet.